BCL2 and JUNB abnormalities in primary cutaneous lymphomas

British Journal of Dermatology

Volumn 151, Issue 3, 2004, Pages 546-556

  Mao, Xin ^a,b   Orchard, G ^a   Lillington, D M ^b   Child, F J ^a   Vonderheid, E C ^c   Nowell, P C ^d   Bagot, M ^e   Bensussan, A ^f   Russell Jones, R ^a   Young, B D ^b   Whittaker, S J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HENRI MONDOR HOSPITAL   (France)

^f FACULTÉ DE MÉDECINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN BCL 2; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEZARY SYNDROME; SIGNAL TRANSDUCTION; SKIN LYMPHOMA;

GENES, BCL-2; GENES, JUN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, KI-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; SEZARY SYNDROME; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 4944231502     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06106.x     Document Type: Article

References (65)

1. Meijerink JP. t(14;18), a journey to eternity. Leukemia 1997: 11: 2175-87.
2. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-56.
3. Mao X, Lillington D, Child FJ et al. Comparative genomic hybridisation analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. Genes Chromosomes Cancer 2002; 35: 144-55.
4. Child FJ, Russell-Jones R, Woolford AJ et al. Absence of the t(14;18) translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 735-44.
5. Vaux DL, Cory S. Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
6. Hockenbery D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
7. Korsmeyer SJ, McDonnell TJ, Nunez G et al. Bcl-2: B cell life, death and neoplasia. Curr Top Microbiol Immunol 1990; 166: 203-7.
8. Nacheva E, Dyer MJ, Metivier C et al. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 1994; 84: 3422-8.
9. Pietenpol JA, Papadopoulos N, Markowitz S et al. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994; 54: 3714-17.
10. Loro LL, Vintermyr OK, Liavaag PG et al. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expression ratio and increased apoptosis. Hum Pathol 1999; 30: 1097-105.
11. Loro LL, Johannessen AC, Vintermyr OK. Decreased expression of bcl-2 in moderate and severe oral epithelia dysplasias. Oral Oncol 2002; 38: 691-8.
12. Guo XZ, Shao XD, Liu MP et al. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World Gastroenterol 2002; 8: 1059-62.
13. Lorsbach RB, Shay-Seymore D, Moore J et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99: 1959-64.
14. Park SH, Kim H, Song BJ. Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res 2002; 8: 26-30.
15. Underhill GH, George D, Bremer EG et al. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 2003; 101: 4013-21.
16. Kari L, Loboda A, Nebozhyn M et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477-88.
17. Passegue E, Jochum W, Schorpp-Kistner M et al. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001; 104: 21-32.
18. Mao X, Orchard G, Lillington D et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003; 101: 1513-19.
19. Bagot M, Echchakir H, Mami-Chouaib F et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+ CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998; 91: 4331-41.
20. Poszepczynska E, Bagot M, Echchakir H et al. Functional characterization of an IL-7-dependent CD4(+) CD8alphaalpha(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 2000; 96: 1056-63.
21. Mao X, Orchard G, Lillington D et al. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37: 176-85.
22. Mao X, Onadim Z, Price EA et al. Genomic alterations in biastic natural killer/extranodal natural killer-like T-cell lymphoma with cutaneous involvement. J Invest Dermatol 2003; 121: 618-27.
23. Mao X, Lillington DM, Czepulkowski B et al. A case of adult T-cell leukaemia/lymphoma characterized by multiplex-fluorescent in situ hybridization, comparative genomic hybridization, fluorescent in situ hybridization and cytogenetics. Br J Dermatol 2001; 145: 117-22.
24. Mao X, Lillington D, Scarisbrick JJ et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas; identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol 2002; 147: 464-75.
25. Mao X, Lillington D, Czepulkowski B et al. Molecular cytogenetic characterisation of Sézary syndrome. Genes Chromosomes Cancer 2003: 36: 250-60.
26. Debernardi S, Lillington DM, Chaplin T et al Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003; 37: 149-58.
27. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-62.
28. Storz MN, van de Rijn M, Kim YH et al. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol 2003; 120: 865-70.
29. Alizadeh AA, Staudt LM. Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol 2000; 12: 219-25.
30. Veis DJ, Sorenson CM, Shutter JR et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-40.
31. Nakayama K, Nakayama K, Negishi I et al Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 1994; 91: 3700-4.
32. Williams O, Brady HJ. The role of molecules that mediate apoptosis in T-cell selection. Trends Immunol 2001; 22: 107-11.
33. McDonnell TJ, Deane N, Platt FM et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
34. McDonnell TJ, Nunez G, Platt FM et al Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Moll Cell Biol 1990; 10; 1901-7.
35. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254-6.
36. Strasser A, Harris AW, Cory S. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 1993; 8: 1-9.
37. Strasser A, Harris AW, Corcoran LM et al. Bcl-2 expression promotes B- but not T-lymphoid development in seid mice. Nature 1994; 368: 457-60.
38. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-12.
39. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-400.
40. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
41. Schorpp-Kistner M, Wang ZQ, Angel P et al. JunB is essential for mammalian placentation. EMBO J 1999; 18: 934-48.
42. Li B, Tournier C, Davis RJ et al. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J 1999; 18: 420-32.
43. Hartenstein B, Teurich S, Hess J et al. Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J 2002; 21: 6321-9.
44. Pachernik J, Soucek K, Hampl A et al. Transforming growth factor-betal induces junB mRNA accumulation, G1-phase arrest, and pRb dephosphorylation in human leukemia HL-60 cells. Folia Biol (Praha) 2001; 47: 32-5.
45. Vowels BR, Lessin SR, Cassin M et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-73.
46. Dummer R, Heald PW, Nestle FO et al Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996; 88: 1383-9.
47. Rook AH, Gottlieb SL, Wolfe JT et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997; 107 (Suppl. 1): 16-20.
48. Bagot M, Nikolova M, Schirm-Chabanette F et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann NY Acad Sci 2001; 941: 31-8.
49. Watanabe M, Ogawa Y, Ito K et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 2003; 163: 633-41.
50. Jaffe ES, Harris NL, Stein H et al. World Health Organization Classification of Tumours-Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
51. Lotem J, Sachs L. Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds. Proc Natl Acad Sci USA 1998; 95: 4601-6.
52. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 2002; 13: 229-37.
53. Ni X, Hazarika P, Zhang C et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-92.
54. Vermeer MH, Doom R, Dukers D et al CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-9.
55. Boise LH, Petryniak B, Mao X et al. The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. Mol Cell Biol 1993; 13: 1911-19.
56. Kaminski BA, Kadereit S, Miller RE et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 2003; 102: 4608-17.
57. Bueno OF, Brandt EB, Rothenberg ME et al. Defective T cell development and function in calcineurin A beta-deficient mice. Proc Natl Acad Sci USA 2002; 99: 9398-403.
58. McCaffrey PG, Luo C, Kerppola TK et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993; 262: 750-4.
59. Szremska AP, Kenner L, Weisz E et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003; 102: 4159-65.
60. Mitchell T, Whittaker S, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of Stat5-dependent gene expression in Sézary syndrome. Cancer Res 2003; 63: 9048-54.
61. Qin JZ, Zhang CL, Kamarashev J et al. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001; 98: 2778-83.
62. Rassidakis GZ, Jones D, Lai R et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol 2003; 200: 240-8.
63. Dummer R, Michie SA, Kell D et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995; 22: 11-17.
64. Zhang CL, Kamarashev J, Qin JZ et al. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 2003; 200: 249-54.
65. Scarisbrick JJ, Mitchell TJ, Calonje E et al. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894-901.